S1:E1 FULL CIRCLE

February 7, 2025

Get to know The Therapeutic Innovations group; who we are, where we came from, and what we’re hoping to achieve. We will go into multiple biologic therapeutic platforms, and how the evolution of the monoclonal antibody is being mirrored by those of next-generation therapeutics. And finally, how older platforms are gradually coming back as new therapies are hitting bumps in the road of development. 

doi.org/10.1186/s12929-019-0592-z

https://www.fda.gov/drugs/spotlight-cder-science/bispecific-antibodies-area-research-and-clinical-applications 

doi.org/10.3390/cancers15153886 

doi:10.46989/ 001c.124277 

S1:E2 So Apparently IPSCs Are Magic; Anyone See the Instruction Manual?

March 2025

For our second episode of Drug Discovery Diaries, the crew dives into IPSC based Drug Therapies: what makes them magical (maybe?) and what makes them challenging. We discuss personal experiences in the field and highlight where the field has been and where is it going.